Functions for Myosin VI in the kidney proximal tubule

肌球蛋白 VI 在肾近曲小管中的功能

基本信息

  • 批准号:
    7163713
  • 负责人:
  • 金额:
    $ 32.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-01-01 至 2009-12-31
  • 项目状态:
    已结题

项目摘要

The general objective of the proposed studies is to continue the molecular and functional characterization of myosin-VI (Myo6). Myo6 is unique among known members of the myosin superfamily of actin based molecular motors in that it moves in the opposite direction along the actin filament, toward the pointed/minus end. Past studies have implicated several potential functions for Myo6 including clathrin mediated endocytosis, Golgi traffic and cellular motility. The health relevance of the proposed studies has been well established as this myosin is a target for mutations that lead to inherited deafness and cardiac myopathies. It also has been shown to be a key contributor to the invasiveness of ovarian tumor cells. The goals of this project are three fold. The first will be to conduct an extensive characterization of the motor properties of native tissue purified Myo6. Our studies indicate that native Myo6 has properties significantly different from in-vitro expressed Myo6. Proposed studies will examine the motility of native Myo6 with respect to duty ratio and regulation by calcium, phosphorylation and load. A major focus will be the molecular basis for the conversion of Myo6 from a minus- to a plus- end directed motor. The second goal will be the phenotypic characterization of the cellular and physiologic defects in the proximal tubule epithelial (PTE) cells of the kidney in the Myo6 mutant mouse?Snell's waltzer. Like humans with Myo6 mutations, these mice are deaf due to degeneration of the neurosensory epithleum of the inner ear. Although this is the only overt dysfunction in these mice, our preliminary findings indicate that there are also serious cellular deficiencies in a number of tissues that express Myo6 including the renal proximal tubule. Studies will include assessment of defects in PTE architecture, endocytosis of glomerular filtrate, and responses to renal injuries including ischemia and chemically induced diabetes. The third goal will focus on the in vivo dynamics of fluorescently tagged Myo6 expressed in a PTE cell line and how cellular functions including endocytosis, wound healing and organization of the actin cytoskeleton are affected by targeted disruption of Myo6 function.
拟议研究的总体目标是继续肌球蛋白-VI (Myo6) 的分子和功能表征。 Myo6 在基于肌动蛋白的分子马达的肌球蛋白超家族的已知成员中是独特的,因为它沿着肌动蛋白丝以相反的方向向尖/负端移动。过去的研究表明 Myo6 具有多种潜在功能,包括网格蛋白介导的内吞作用、高尔基体运输和细胞运动。拟议研究的健康相关性已得到充分证实,因为这种肌球蛋白是导致遗传性耳聋和心肌病的突变目标。它还被证明是卵巢肿瘤细胞侵袭性的关键因素。该项目的目标有三个。首先是对电机特性进行广泛的表征 天然组织纯化的 Myo6。我们的研究表明,天然 Myo6 的特性与体外表达的 Myo6 显着不同。拟议的研究将检查天然 Myo6 在占空比和钙调节、磷酸化和负载方面的运动性。主要关注点是 Myo6 从负端定向电机转换为正端定向电机的分子基础。第二个目标是 Myo6 突变小鼠肾脏近端小管上皮 (PTE) 细胞的细胞和生理缺陷的表型特征?Snell's waltzer。与携带 Myo6 突变的人类一样,这些小鼠由于内耳神经感觉上皮的退化而失聪。尽管这是这些小鼠中唯一明显的功能障碍,但我们的初步研究结果表明,包括肾近曲小管在内的许多表达 Myo6 的组织也存在严重的细胞缺陷。研究将包括评估 PTE 结构缺陷、肾小球滤液内吞作用以及对肾损伤(包括缺血和化学诱导的糖尿病)的反应。第三个目标将重点关注 PTE 细胞系中表达的荧光标记 Myo6 的体内动态,以及靶向破坏 Myo6 功能如何影响细胞功能,包括内吞作用、伤口愈合和肌动蛋白细胞骨架的组织。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK S MOOSEKER其他文献

MARK S MOOSEKER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK S MOOSEKER', 18)}}的其他基金

Functions for Myosin VI in the kidney proximal tubule
肌球蛋白 VI 在肾近曲小管中的功能
  • 批准号:
    7034337
  • 财政年份:
    2006
  • 资助金额:
    $ 32.49万
  • 项目类别:
Functions for Myosin VI in the kidney proximal tubule
肌球蛋白 VI 在肾近曲小管中的功能
  • 批准号:
    7337308
  • 财政年份:
    2006
  • 资助金额:
    $ 32.49万
  • 项目类别:
Functions for Myosin VI in the kidney proximal tubule
肌球蛋白 VI 在肾近曲小管中的功能
  • 批准号:
    7615036
  • 财政年份:
    2006
  • 资助金额:
    $ 32.49万
  • 项目类别:
TRANSMISSION ELECTRON MICROSCOPY INSTRUMENTATION: NEUROSCIENCE
透射电子显微镜仪器:神经科学
  • 批准号:
    6973364
  • 财政年份:
    2004
  • 资助金额:
    $ 32.49万
  • 项目类别:
TRANSMISSION ELECTRON MICROSCOPY INSTRUMENTATION: CELL BIOLOGY
透射电子显微镜仪器:细胞生物学
  • 批准号:
    6973365
  • 财政年份:
    2004
  • 资助金额:
    $ 32.49万
  • 项目类别:
Transmission Electron Microscopy Instrumentation
透射电子显微镜仪器
  • 批准号:
    6730833
  • 财政年份:
    2004
  • 资助金额:
    $ 32.49万
  • 项目类别:
PROTEINS ASSOCIATED WITH A MYO2P RNP
与 MYO2P RNP 相关的蛋白质
  • 批准号:
    6979649
  • 财政年份:
    2004
  • 资助金额:
    $ 32.49万
  • 项目类别:
PILOT STUDY--HEPATOCYTE UNCONVENTIONAL MYOSINS
试点研究--肝细胞非常规肌球蛋白
  • 批准号:
    6270605
  • 财政年份:
    1998
  • 资助金额:
    $ 32.49万
  • 项目类别:
PILOT STUDY--HEPATOCYTE UNCONVENTIONAL MYOSINS
试点研究--肝细胞非常规肌球蛋白
  • 批准号:
    6105287
  • 财政年份:
    1998
  • 资助金额:
    $ 32.49万
  • 项目类别:
PILOT STUDY--HEPATOCYTE UNCONVENTIONAL MYOSINS
试点研究--肝细胞非常规肌球蛋白
  • 批准号:
    6238870
  • 财政年份:
    1997
  • 资助金额:
    $ 32.49万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.49万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.49万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 32.49万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.49万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.49万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.49万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 32.49万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 32.49万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 32.49万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 32.49万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了